With that said, for the third quarter, net sales increased 48% year-over-year to $53.6 million, driven primarily by unit growth. Underlying total prescription data for ARISTADA demonstrated solid growth of 42% year-over-year in terms of months of therapy. Sequentially, ARISTADA net sales increased 11%, also driven by unit growth. Gross-to-net adjustments for ARISTADA were 48.2% for Q3, consistent with the second quarter and our expectation for full-year gross-to-net. Against the backdrop of a long-acting atypical market that has continued to grow at double-digit rates, ARISTADA's market share has also continued to increase.